Impact News +++ Directors’ Dealings News: MAX Automation SE (EQS) +++ MAX AUTOMATION Aktie -8,06%

JOHNSON & JOHNSON Aktie

>J&J Aktienkurs

247.7 EUR +2.0% (TradegateBSX)

Ask: 248.05 EUR / 50 Stück

Bid: 247.75 EUR / 50 Stück

Tagesumsatz: 9738 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

J&J Aktie über LYNX handeln

Intraday

1 Jahr

>J&J Performance

1 Woche: +1,0%

1 Monat: +9,5%

3 Monate: +11,1%

6 Monate: +29,7%

1 Jahr: +53,3%

laufendes Jahr: +40,1%

>JOHNSON & JOHNSON Aktie

Profil:

Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infec..
>Volltext..

Insiderhandel:

>J&J Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>J&J Anleihen

>J&J Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Neurologische Erkrankungen/ Schlaganfälle, Augenmedizin/ Sehhilfen, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
>Alle Branchen..

>J&J Chart & Kurs - NYSE

>J&J News

07.11.26 - 16:45	J&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritis (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.11.26 - 16:06	Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide (PR Newswire)
	Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,......

07.11.26 - 16:06	Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren′s disease that reveal insights on importance of symptom improvements most valued by patients (PR Newswire)
	New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more......

06.11.26 - 19:45	JNJ′s Innovative Medicine Unit Grows in Q3 Despite Patent Losses (Zacks)
	J&J's Innovative Medicine sees a 7.7% rise in Q3 sales to $16.76 billion, as blockbuster drugs and new launches offset generic headwinds....

06.11.26 - 16:00	U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme′s ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer (PR Newswire)
	Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug......

06.11.26 - 03:30	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ (PR Newswire)
	NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......

06.11.26 - 03:27	Johnson & Johnson wins FDA approval for Rybrevant cancer treatment (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.26 - 03:24	Johnson & Johnson erhält FDA-Zulassung für Krebstherapie Rybrevant (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.26 - 03:06	Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer (PR Newswire)
	Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a......

06.11.26 - 01:57	J&J gains approval of Rybrevant Faspro for head and neck cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.26 - 19:01	BAYRY vs. JNJ: Which Stock Is the Better Value Option? (Zacks)
	BAYRY vs. JNJ: Which Stock Is the Better Value Option?...

04.11.26 - 16:00	Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink? (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

04.11.26 - 11:12	Smith & Nephew cuts 2026 outlook; talks with Johnson & Johnson end (Alliance)
	Smith & Nephew PLC on Wednesday cut its 2026 guidance as weaker-than-expected growth in its US Orthopaedics business weighed...

04.11.26 - 08:48	Smith+Nephew cuts outlook, confirms failed merger talks with J&J′s orthopaedics unit (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.11.26 - 18:24	The Best Dividend Stocks to Buy With $5,000 in November (Fool)
	AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market....

02.11.26 - 01:03	Johnson & Johnson reports 94% success rate in trial of coronary artery device (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.11.26 - 16:18	Johnson & Johnson reports lower mortality rates with Impella heart pumps (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.10.26 - 03:24	Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here′s What That Tells Investors. (Fool)
	Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more....

30.10.26 - 18:18	The big winners of the tech wreck are biopharma stocks (MarketWatch)
	The shares of large drugmakers like Lilly, Gilead and J&J keep hitting record highs....

30.10.26 - 17:15	JNJ′s MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? (Zacks)
	J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Bei Wahlen ist es eine Selbstverständlichkeit, daß Dackel gegen Rennpferde starten. - Arsenio Hall

Partner: >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram